Hyperinflammation and Hyperferritinemia in Critically Ill Patients (HYFER)

February 6, 2025 updated by: Thomas Karvunidis, Charles University, Czech Republic

Hyperinflammation and Hyperferritinemia in Critically Ill Patients: a Retrospective Observational Single-center Analysis

Analysing trajectory of critically ill patients with signs of hyperinflammation

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1962

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Czech Republic
      • Pilsen, Czech Republic, 30460
        • Faculty of Medicine and Teaching Hospital, Charles University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

critically ill patients; mix-cases medical ICU population

Description

Inclusion Criteria:

  • critically ill patients
  • admission between 01.01.2020 and 31.12.2024 (5yrs)

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
critically ill patients
critically ill patients admitted to ICU between 01.01.2020 and 31.12.2024

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hyperferritinemia
Time Frame: 2025
trajectory of critically ill patients with significant hyperferritinemia and with regard to its dynamics; ferritin value cutt-off
2025

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
etiology and association of hyperferritinemia
Time Frame: 2025
etiology and association of hyperferritinemia with infectioius a non-infectious diseases/conditions
2025
mortality a morbidity
Time Frame: 2025
mortality a morbidity of patients with significant hyperferritinemia
2025
treatment strategy
Time Frame: 2025
association of hyperferritinemia and treatment strategy
2025
stratification
Time Frame: 2025
patient stratification according to hyperferritinemia/hyperinflammation
2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Charles University, Czech Republic

Investigators

  • Principal Investigator: Thomas Karvunidis, MD, PhD, Faculty of Medicine and Teaching Hospital, Charles University, Pilsen, Czech Republic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 20, 2025

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

November 30, 2025

Study Registration Dates

First Submitted

February 6, 2025

First Submitted That Met QC Criteria

February 6, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 6, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HYFER_2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe